Clinical Trial Update: Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on durvalumab combined with neoadjuvant chemotherapy for resectable biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Resectable Biliary Tract Cancer | Phase 2 | Status: UNKNOWN